Ursodiol disulfate

Drug Profile

Ursodiol disulfate

Alternative Names: Disulfate conjugate of ursodeoxycholate (SUDCA); SUDCA; Ursodeoxycholic acid-disulfate

Latest Information Update: 11 Aug 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cincinnati Childrens Hospital Medical Center
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Colorectal cancer; Liver transplant rejection

Most Recent Events

  • 25 Feb 2008 Axcan Pharma has been acquired by Texas Pacific Group
  • 23 Feb 2007 Discontinued - Preclinical for Liver transplant rejection in Canada (IV)
  • 30 Sep 2006 Axcan completes a second phase I trial in Colorectal cancer in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top